Search
Repotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigationalRepotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the … [A262056] Repotrectinib possesses a compact macrocyclic structure that both limits adverse interactions with resistance mutation hotspots and targets mutations in the solvent-front region.
Synonyms: (3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONESalsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSalsalate's mode of action as an anti-inflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. … Salsalate is a nonsteroidal anti-inflammatory agent for oral administration.
Protriptyline
go.drugbank.com/drugs/DB00344ApprovedThe antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. … See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.
Synonyms: 5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene, 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amineInfigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment … Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor.
Lomitapide
go.drugbank.com/drugs/DB08827ApprovedLomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP). … [A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexTU-100
go.drugbank.com/drugs/DB12467InvestigationalTU-100 has been used in trials studying the treatment of Abdominal Pain, Colonic Transit, Crohn's Disease, Rectal Sensation, and Gastric Emptying, among others.
Grapiprant
go.drugbank.com/drugs/DB12836InvestigationalVet approvedGrapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class. … [L4766] Grapiprant has been approved in March 2016 by the FDA's Center for Veterinary Medicine as a non-cyclooxygenase inhibiting NSAID for veterinary use.[A39836]
Brinzolamide
go.drugbank.com/drugs/DB01194Approved[A2051] Brinzolamide was approved by the FDA in 1998 as a standalone product and in 2013 as a combination product with brimonidine tartrate. … Brinzolamide is a highly specific, non-competitive, reversible carbonic anhydrase II (CA-II) inhibitor indicated to reduce ocular pressure in patients with ocular hypertension or open-angle glaucoma.
Products: BRINZOLAMID AL 10MG/ML, BRINZOLAMID 1A PHAR10MG/MLPrasterone
go.drugbank.com/drugs/DB01708ApprovedInvestigationalNutraceuticalIn November 2016, DHEA was approved (as Intrarosa) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause … In Canada, a prescription is required to buy DHEA.
International brands: OVIGYN-DMipomersen
go.drugbank.com/drugs/DB05528ApprovedDue to this serious risk of liver toxicity, mipomersen sodium is only available to patients under the restricted program called Kynamro Risk Evaluation and Mitigation Strategy program. … Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide.
Categories: Compounds used in a research, industrial, or household setting